US6407132B1
(en)
*
|
1997-07-25 |
2002-06-18 |
James Black Foundation Limited |
Substituted imidazole derivatives and their use as histamine H3 receptor ligands
|
GB9718913D0
(en)
*
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
DE19816624A1
(de)
*
|
1998-04-15 |
1999-10-21 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6319918B1
(en)
|
1998-06-04 |
2001-11-20 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones with kinase inhibitory activity
|
DE19824922A1
(de)
*
|
1998-06-04 |
1999-12-09 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
WO2000035921A1
(en)
|
1998-12-17 |
2000-06-22 |
F. Hoffmann-La Roche Ag |
4,5-pyrazinoxindoles as protein kinase inhibitors
|
KR100649925B1
(ko)
|
1998-12-17 |
2007-02-28 |
에프. 호프만-라 로슈 아게 |
싸이클린-의존성 키나제, 특히 cdk2 의 저해제로서4-알케닐 (및 알키닐) 옥신돌
|
PT1149106E
(pt)
*
|
1998-12-17 |
2003-06-30 |
Hoffmann La Roche |
4,5-azolo-oxindois
|
US6153634A
(en)
|
1998-12-17 |
2000-11-28 |
Hoffmann-La Roche Inc. |
4,5-azolo-oxindoles
|
CA2354591A1
(en)
|
1998-12-17 |
2000-06-22 |
F. Hoffmann-La Roche Ag |
4-aryloxindoles as inhibitors of jnk protein kinases
|
WO2000042213A1
(en)
|
1999-01-13 |
2000-07-20 |
The Research Foundation Of State University Of New York |
A novel method for designing protein kinase inhibitors
|
GB9904930D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Thiazoloindolinone compounds
|
US6492398B1
(en)
*
|
1999-03-04 |
2002-12-10 |
Smithkline Beechman Corporation |
Thiazoloindolinone compounds
|
GB9904932D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy
|
US6624171B1
(en)
|
1999-03-04 |
2003-09-23 |
Smithkline Beecham Corporation |
Substituted aza-oxindole derivatives
|
GB9904933D0
(en)
*
|
1999-03-04 |
1999-04-28 |
Glaxo Group Ltd |
Compounds
|
US6462032B1
(en)
|
1999-05-04 |
2002-10-08 |
Wyeth |
Cyclic regimens utilizing indoline derivatives
|
US6358947B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Tetracyclic progesterone receptor modulator compounds and methods
|
US6380235B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Benzimidazolones and analogues
|
US6407101B1
(en)
|
1999-05-04 |
2002-06-18 |
American Home Products Corporation |
Cyanopyrroles
|
US6444668B1
(en)
|
1999-05-04 |
2002-09-03 |
Wyeth |
Combination regimens using progesterone receptor modulators
|
US6498154B1
(en)
|
1999-05-04 |
2002-12-24 |
Wyeth |
Cyclic regimens using quinazolinone and benzoxazine derivatives
|
US6369056B1
(en)
|
1999-05-04 |
2002-04-09 |
American Home Products Corporation |
Cyclic urea and cyclic amide derivatives
|
US6417214B1
(en)
|
1999-05-04 |
2002-07-09 |
Wyeth |
3,3-substituted indoline derivatives
|
US6509334B1
(en)
|
1999-05-04 |
2003-01-21 |
American Home Products Corporation |
Cyclocarbamate derivatives as progesterone receptor modulators
|
US6339098B1
(en)
|
1999-05-04 |
2002-01-15 |
American Home Products Corporation |
2,1-benzisothiazoline 2,2-dioxides
|
US6329416B1
(en)
|
1999-05-04 |
2001-12-11 |
American Home Products Corporation |
Combination regimens using 3,3-substituted indoline derivatives
|
US6399593B1
(en)
|
1999-05-04 |
2002-06-04 |
Wyeth |
Cyclic regimens using cyclic urea and cyclic amide derivatives
|
US6319912B1
(en)
|
1999-05-04 |
2001-11-20 |
American Home Products Corporation |
Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
|
US6391907B1
(en)
*
|
1999-05-04 |
2002-05-21 |
American Home Products Corporation |
Indoline derivatives
|
US6423699B1
(en)
|
1999-05-04 |
2002-07-23 |
American Home Products Corporation |
Combination therapies using benzimidazolones
|
US6358948B1
(en)
|
1999-05-04 |
2002-03-19 |
American Home Products Corporation |
Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
|
US6380178B1
(en)
|
1999-05-04 |
2002-04-30 |
American Home Products Corporation |
Cyclic regimens using cyclocarbamate and cyclic amide derivatives
|
US6306851B1
(en)
|
1999-05-04 |
2001-10-23 |
American Home Products Corporation |
Cyclocarbamate and cyclic amide derivatives
|
US6355648B1
(en)
|
1999-05-04 |
2002-03-12 |
American Home Products Corporation |
Thio-oxindole derivatives
|
GB9911053D0
(en)
*
|
1999-05-12 |
1999-07-14 |
Pharmacia & Upjohn Spa |
4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
|
DE19924401A1
(de)
*
|
1999-05-27 |
2000-11-30 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
WO2001016130A1
(de)
*
|
1999-08-27 |
2001-03-08 |
Boehringer Ingelheim Pharma Kg |
Substituierte indolinone als tyrosinkinase inhibitoren
|
ES2279769T3
(es)
*
|
1999-09-24 |
2007-09-01 |
Smithkline Beecham Corporation |
Mimeticos de trombopoyetina.
|
UA75054C2
(uk)
*
|
1999-10-13 |
2006-03-15 |
Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг |
Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
|
DE19949209A1
(de)
*
|
1999-10-13 |
2001-04-19 |
Boehringer Ingelheim Pharma |
In 5-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6762180B1
(en)
|
1999-10-13 |
2004-07-13 |
Boehringer Ingelheim Pharma Kg |
Substituted indolines which inhibit receptor tyrosine kinases
|
US6313310B1
(en)
|
1999-12-15 |
2001-11-06 |
Hoffmann-La Roche Inc. |
4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles
|
YU54202A
(sh)
|
2000-01-18 |
2006-01-16 |
Agouron Pharmaceuticals Inc. |
Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
|
HN2001000008A
(es)
|
2000-01-21 |
2003-12-11 |
Inc Agouron Pharmaceuticals |
Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
|
AU2001236720A1
(en)
*
|
2000-02-05 |
2001-08-14 |
Bemis, Guy |
Compositions useful as inhibitors of erk
|
US6620818B1
(en)
|
2000-03-01 |
2003-09-16 |
Smithkline Beecham Corporation |
Method for reducing the severity of side effects of chemotherapy and/or radiation therapy
|
WO2001079198A1
(en)
|
2000-04-18 |
2001-10-25 |
Agouron Pharmaceuticals, Inc. |
Pyrazoles for inhibiting protein kinase
|
UA73119C2
(en)
|
2000-04-19 |
2005-06-15 |
American Home Products Corpoir |
Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
|
US6534531B2
(en)
*
|
2000-04-27 |
2003-03-18 |
Bristol-Myers Squibb Company |
Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
|
WO2001082967A1
(en)
*
|
2000-04-28 |
2001-11-08 |
Yamanouchi Pharmaceutical Co., Ltd. |
MEDICINAL COMPOSITIONS FOR SUPPRESSING β-AMYLOID PRODUCTION
|
CY2010012I2
(el)
|
2000-05-25 |
2020-05-29 |
Novartis Ag |
Μιμητικα θρομβοποιητινης
|
GB0016454D0
(en)
|
2000-07-04 |
2000-08-23 |
Hoffmann La Roche |
Thienopyrrolidinones
|
CA2411928A1
(en)
|
2000-08-09 |
2002-02-14 |
Agouron Pharmaceuticals, Inc. |
Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclindependent kinases
|
ES2238463T3
(es)
|
2000-08-18 |
2005-09-01 |
Agouron Pharmaceuticals, Inc. |
Hidroxiimino-fluorenos heterociclicos y uso para inhibir proteina-quinasas.
|
ES2230337T3
(es)
*
|
2000-09-01 |
2005-05-01 |
Glaxo Group Limited |
Derivados de oxindol.
|
JP2004517049A
(ja)
*
|
2000-09-01 |
2004-06-10 |
グラクソ グループ リミテッド |
チロシンキナーゼ阻害剤としての置換オキシインドール誘導体
|
EP1317446A1
(en)
*
|
2000-09-01 |
2003-06-11 |
Glaxo Group Limited |
Oxindole derivatives
|
EP1201765A3
(en)
*
|
2000-10-16 |
2003-08-27 |
Axxima Pharmaceuticals Aktiengesellschaft |
Cellular kinases involved in cytomegalovirus infection and their inhibition
|
DE10054019A1
(de)
*
|
2000-11-01 |
2002-05-23 |
Boehringer Ingelheim Pharma |
Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
US6638965B2
(en)
|
2000-11-01 |
2003-10-28 |
Boehringer Ingelheim Pharma Kg |
Substituted indolinones, preparation thereof and their use as pharmaceutical compositions
|
DE10117204A1
(de)
|
2001-04-06 |
2002-10-10 |
Boehringer Ingelheim Pharma |
In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
|
SE0101230L
(sv)
*
|
2001-04-06 |
2002-10-07 |
Innoventus Project Ab |
Ny användning av en tyrosinkinasinhibitor
|
WO2002094809A1
(en)
*
|
2001-05-24 |
2002-11-28 |
Yamanouchi Pharmaceutical Co., Ltd. |
3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
|
ATE330608T1
(de)
|
2001-06-29 |
2006-07-15 |
Ab Science |
Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
|
CA2452392A1
(en)
|
2001-06-29 |
2003-01-16 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd)
|
WO2003003006A2
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
New potent, selective and non toxic c-kit inhibitors
|
EP1450775B1
(en)
*
|
2001-09-20 |
2008-03-12 |
AB Science |
C-kit inhibitors for treating bacterial infections
|
EP1461032B1
(en)
*
|
2001-09-20 |
2008-07-16 |
AB Science |
Use of c-kit inhibitors for promoting hair growth
|
WO2003027109A1
(en)
*
|
2001-09-27 |
2003-04-03 |
Allergan, Inc. |
3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
|
AU2002341881B2
(en)
*
|
2001-09-27 |
2008-05-08 |
Allergan, Inc. |
3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
|
WO2003033491A1
(fr)
*
|
2001-10-16 |
2003-04-24 |
Nippon Kayaku Kabushiki Kaisha |
Composition medicinale de prevention ou de soulagement d'effets secondaires chez les patients souffrant de cancer et composition anticancereuse medicinale
|
CA2464214C
(en)
*
|
2001-10-22 |
2011-02-08 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
|
US7005445B2
(en)
|
2001-10-22 |
2006-02-28 |
The Research Foundation Of State University Of New York |
Protein kinase and phosphatase inhibitors and methods for designing them
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
US6797825B2
(en)
|
2001-12-13 |
2004-09-28 |
Abbott Laboratories |
Protein kinase inhibitors
|
AU2002354499A1
(en)
*
|
2001-12-18 |
2003-06-30 |
Kyowa Hakko Kogyo Co., Ltd. |
Indole derivative
|
US7482366B2
(en)
*
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
EP1465869B1
(en)
|
2001-12-21 |
2013-05-15 |
Exelixis Patent Company LLC |
Modulators of lxr
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
FR2836914B1
(fr)
*
|
2002-03-11 |
2008-03-14 |
Aventis Pharma Sa |
Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
|
CA2482789A1
(en)
*
|
2002-04-30 |
2003-11-13 |
Alcon, Inc. |
Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treatglaucomatous retinopathies/optic neuropathies
|
TWI280128B
(en)
|
2002-05-22 |
2007-05-01 |
Smithkline Beecham Corp |
3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
|
US7169936B2
(en)
|
2002-07-23 |
2007-01-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
|
US7514468B2
(en)
|
2002-07-23 |
2009-04-07 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
|
DE10233500A1
(de)
*
|
2002-07-24 |
2004-02-19 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylen]-6-methoxycarbonyl-2-indolinon-Monoethansulfonat und dessen Verwendung als Arzneimittel
|
US20040082615A1
(en)
*
|
2002-08-07 |
2004-04-29 |
Michael Konkel |
3-Imino-2-indolones for the treatement of depression and/or anxiety
|
TW200410937A
(en)
*
|
2002-08-07 |
2004-07-01 |
Synaptic Pharma Corp |
3-imino-2-indolones for the treatment of depression and/or anxiety
|
GB0225873D0
(en)
*
|
2002-11-06 |
2002-12-11 |
Cyclacel Ltd |
Combination
|
AU2003284572A1
(en)
*
|
2002-11-22 |
2004-06-18 |
Yamanouchi Pharmaceutical Co., Ltd. |
2-oxoindoline derivatives
|
WO2004057340A1
(en)
|
2002-12-23 |
2004-07-08 |
Astex Technology Limited |
Synthesis and screening of ligands using x-ray crystallography
|
PT1656372E
(pt)
|
2003-07-30 |
2013-06-27 |
Rigel Pharmaceuticals Inc |
Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
|
TW200526638A
(en)
|
2003-10-22 |
2005-08-16 |
Smithkline Beecham Corp |
2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
|
GB0328180D0
(en)
*
|
2003-12-04 |
2004-01-07 |
Cyclacel Ltd |
Combination
|
DE102004012069A1
(de)
*
|
2004-03-12 |
2005-09-29 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
|
WO2005118551A2
(en)
*
|
2004-05-28 |
2005-12-15 |
Ligand Pharmaceuticals Inc. |
Thrombopoietin activity modulating compounds and methods
|
MX2007004765A
(es)
*
|
2004-10-25 |
2007-07-09 |
Ligand Pharm Inc |
Compuestos y metodos que modulan la actividad de la trombopoyetina.
|
GT200500321A
(es)
*
|
2004-11-09 |
2006-09-04 |
|
Compuestos y composiciones como inhibidores de proteina kinase.
|
AU2005311251A1
(en)
|
2004-12-01 |
2006-06-08 |
Devgen Nv |
5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
|
ES2387927T3
(es)
*
|
2004-12-17 |
2012-10-04 |
Devgen Nv |
Composiciones nematicidas
|
PE20060777A1
(es)
*
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
WO2006101937A1
(en)
*
|
2005-03-18 |
2006-09-28 |
Janssen Pharmaceutica N.V. |
Acylhydrazones as kinase modulators
|
WO2006119660A1
(en)
*
|
2005-05-11 |
2006-11-16 |
Givaudan Sa |
Encapsulation method
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
SG137989A1
(en)
|
2005-06-08 |
2008-01-28 |
Rigel Pharmaceuticals Inc |
Compositions and methods for inhibition of the JAK pathway
|
WO2007008985A2
(en)
*
|
2005-07-13 |
2007-01-18 |
Allergan, Inc. |
Kinase inhibitors
|
US7692005B2
(en)
|
2005-07-13 |
2010-04-06 |
Allergan, Inc. |
Kinase inhibitors
|
US7749530B2
(en)
|
2005-07-13 |
2010-07-06 |
Allergan, Inc. |
Kinase inhibitors
|
GB0523041D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Cyclacel Ltd |
Combination
|
EP1991532B1
(en)
|
2006-02-24 |
2017-01-11 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US8987474B2
(en)
*
|
2006-04-07 |
2015-03-24 |
University Of South Florida |
Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs
|
US7838542B2
(en)
|
2006-06-29 |
2010-11-23 |
Kinex Pharmaceuticals, Llc |
Bicyclic compositions and methods for modulating a kinase cascade
|
US8217177B2
(en)
*
|
2006-07-14 |
2012-07-10 |
Amgen Inc. |
Fused heterocyclic derivatives and methods of use
|
US8036664B2
(en)
*
|
2006-09-22 |
2011-10-11 |
Kineto Wireless, Inc. |
Method and apparatus for determining rove-out
|
CA2664147A1
(en)
*
|
2006-10-06 |
2008-04-17 |
Irm Llc |
Protein kinase inhibitors and methods for using thereof
|
GB0625283D0
(en)
*
|
2006-12-19 |
2007-01-24 |
Cyclacel Ltd |
Combination
|
EP2366703B1
(en)
*
|
2007-02-13 |
2014-07-30 |
AB Science |
Polymorph form of 2-amino (nitroaryl) thiazole derivative
|
US20100143440A1
(en)
*
|
2007-04-30 |
2010-06-10 |
The Uab Research Foundation |
Ul97 inhibitors for treatment of proliferative disorders
|
ECSP077628A
(es)
|
2007-05-03 |
2008-12-30 |
Smithkline Beechman Corp |
Nueva composición farmacéutica
|
US7863315B2
(en)
*
|
2008-01-15 |
2011-01-04 |
Shenzhen Chipscreen Biosciences, Ltd. |
2-indolinone derivatives as selective histone deacetylase inhibitors
|
CA2715658C
(en)
|
2008-02-15 |
2016-07-19 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
|
WO2009111644A2
(en)
*
|
2008-03-05 |
2009-09-11 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
NZ589315A
(en)
|
2008-04-16 |
2012-11-30 |
Portola Pharm Inc |
2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
|
EP2116236A1
(en)
|
2008-04-21 |
2009-11-11 |
Université de Mons-Hainaut |
Bisbenzamidine derivatives for use as antioxidant
|
WO2009131687A2
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
WO2009135000A2
(en)
*
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
|
CN102098918A
(zh)
*
|
2008-05-13 |
2011-06-15 |
帕纳德制药公司 |
用于治疗癌症和神经退行性疾病的生物活性化合物
|
CN102088969B
(zh)
|
2008-06-09 |
2013-06-12 |
西克拉塞尔有限公司 |
沙帕他滨或cndac与dna甲基转移酶抑制剂如地西他滨和普鲁卡因的组合
|
JP2012504646A
(ja)
*
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
選択的サイクリン依存性キナーゼ4/6阻害剤を用いた化学療法化合物に対する造血系の防護
|
AU2009310352A1
(en)
*
|
2008-10-01 |
2010-05-06 |
The University Of North Carolina At Chapel Hill |
Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
EP3025724B1
(en)
|
2009-05-13 |
2018-07-11 |
The University of North Carolina At Chapel Hill |
Cyclin dependent kinase inhibitors and methods of use
|
EA024557B1
(ru)
|
2009-05-29 |
2016-09-30 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Способы введения соединений, являющихся агонистами тромбопоэтина
|
RU2557982C2
(ru)
*
|
2009-07-28 |
2015-07-27 |
Райджел Фармасьютикалз, Инк. |
Композиции и способы ингибирования пути jak
|
MX2012003770A
(es)
|
2009-09-30 |
2012-08-03 |
Harvard College |
Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
|
US8652534B2
(en)
*
|
2009-10-14 |
2014-02-18 |
Berry Pharmaceuticals, LLC |
Compositions and methods for treatment of mammalian skin
|
SI2493895T1
(sl)
*
|
2009-10-29 |
2017-10-30 |
Vectura Limited |
Derivati heteroarila, ki vsebujejo N, kot inhibitorji JAK3 kinaze
|
US20120328568A1
(en)
|
2010-02-12 |
2012-12-27 |
Emory University |
Compositions and uses of lectins
|
CA2791338C
(en)
|
2010-03-02 |
2019-06-11 |
Amakem Nv |
Heterocyclic amides as rock inhibitors
|
EP2585463A1
(en)
|
2010-06-25 |
2013-05-01 |
Facultés Universitaires Notre-Dame de la Paix |
Beta carboline derivatives useful in the treatment of proliferative disorders
|
US8785648B1
(en)
|
2010-08-10 |
2014-07-22 |
The Regents Of The University Of California |
PKC-epsilon inhibitors
|
WO2012024489A2
(en)
|
2010-08-18 |
2012-02-23 |
Emory University |
Compounds and compositions for ossification and methods related thereto
|
WO2012022780A1
(en)
|
2010-08-19 |
2012-02-23 |
Université Libre de Bruxelles |
18-beta-glycyrrhetinic acid derivatives with anti-tumor activity
|
EP3381920B1
(en)
|
2010-10-25 |
2019-03-27 |
G1 Therapeutics, Inc. |
Cdk inhibitors
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
WO2012058211A2
(en)
|
2010-10-29 |
2012-05-03 |
Emory University |
Quinazoline derivatives, compositions, and uses related thereto
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
GB201019043D0
(en)
|
2010-11-10 |
2010-12-22 |
Protea Biopharma N V |
Use of 2',5'-oligoadenylate derivative compounds
|
CA2818046A1
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6
|
AU2011336397B2
(en)
|
2010-12-03 |
2016-12-15 |
Emory University |
Chemokine CXCR4 receptor modulators and uses related thereto
|
US8691777B2
(en)
|
2011-01-27 |
2014-04-08 |
Emory University |
Combination therapy
|
CA2827392A1
(en)
|
2011-02-24 |
2012-08-30 |
Emory University |
Noggin blocking compositions for ossification and methods related thereto
|
US11179500B2
(en)
|
2011-02-24 |
2021-11-23 |
Emory University |
JAB1 inhibitory compositions for ossification and methods related thereto
|
US9365523B2
(en)
|
2011-03-31 |
2016-06-14 |
Emory University |
Imidazolyl amide compounds and uses related thereto
|
PL2696878T3
(pl)
|
2011-04-14 |
2020-01-31 |
Cyclacel Limited |
Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej
|
US20140045936A1
(en)
|
2011-04-21 |
2014-02-13 |
Wake Forest University Health Sciences |
Cyclopropyl derivatives and methods of use
|
GB201107223D0
(en)
|
2011-04-29 |
2011-06-15 |
Amakem Nv |
Novel rock inhibitors
|
EP2707034A1
(en)
|
2011-05-09 |
2014-03-19 |
Universiteit Antwerpen |
Activity-based probes for the urokinase plasminogen activator
|
GB201108225D0
(en)
|
2011-05-17 |
2011-06-29 |
Amakem Nv |
Novel KBC inhibitors
|
EP2721011B1
(en)
|
2011-06-20 |
2017-09-06 |
Emory University |
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
|
GB201113689D0
(en)
|
2011-08-09 |
2011-09-21 |
Amakem Nv |
Novel PDE4 inhibitors
|
CA2848726C
(en)
|
2011-08-19 |
2019-09-10 |
Emory University |
Bax agonist, compositions, and methods related thereto
|
GB201114854D0
(en)
|
2011-08-29 |
2011-10-12 |
Amakem Nv |
Novel rock inhibitors
|
EP2751079A1
(en)
|
2011-08-31 |
2014-07-09 |
Amakem NV |
Biphenylcarboxamides as rock kinase inhibitors
|
AU2012314376B2
(en)
|
2011-09-30 |
2017-04-06 |
Oncodesign S.A. |
Macrocyclic FLT3 kinase inhibitors
|
HUE029728T2
(en)
|
2011-09-30 |
2017-03-28 |
Ipsen Pharma Sas |
Macrocyclic LRRK2 kinase inhibitors
|
GB201119358D0
(en)
|
2011-11-10 |
2011-12-21 |
Lewi Paulus J |
Disubstituted triazine dimers for treatment and/or prevention of infectious diseases
|
DE102011119127A1
(de)
*
|
2011-11-22 |
2013-05-23 |
Merck Patent Gmbh |
3-Cyanaryl-1H-pyrrolo[2.3-b]pyridin-Derivate
|
CA2856301C
(en)
|
2011-11-23 |
2020-10-06 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
ES2958619T3
(es)
|
2012-01-30 |
2024-02-12 |
Univ Gent |
Compuestos anti-invasivos
|
GB201204756D0
(en)
|
2012-03-19 |
2012-05-02 |
Lewi Paulus J |
Triazines with suitable spacers for treatment and/or prevention of HIV infections
|
AU2013239816B2
(en)
|
2012-03-29 |
2017-08-24 |
G1 Therapeutics, Inc. |
Lactam kinase inhibitors
|
US20150110723A1
(en)
|
2012-05-31 |
2015-04-23 |
Emory University |
Quinazoline derivatives, compositions, and uses related thereto
|
EP2877461B1
(en)
|
2012-07-27 |
2018-05-09 |
Emory University |
Heterocyclic flavone derivatives, compositions, and methods related thereto
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
WO2014059034A2
(en)
|
2012-10-09 |
2014-04-17 |
President And Fellows Of Harvard College |
Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
EP3369730B1
(en)
|
2012-11-05 |
2020-08-05 |
Emory University |
7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
|
WO2014072419A1
(en)
|
2012-11-08 |
2014-05-15 |
Universiteit Antwerpen |
Novel anti-hiv compounds
|
AU2014211580B2
(en)
|
2013-01-29 |
2018-05-10 |
Redx Pharma Plc |
Pyridine derivatives as soft ROCK inhibitors
|
WO2014144740A2
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
US9572815B2
(en)
|
2013-03-15 |
2017-02-21 |
St. Jude Children's Research Hospital |
Methods and compositions of p27KIP1 transcriptional modulators
|
EP2968291A4
(en)
|
2013-03-15 |
2016-09-28 |
G1 Therapeutics Inc |
HSPC-PROOF TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION
|
WO2014140313A1
(en)
|
2013-03-15 |
2014-09-18 |
Oncodesign S.A. |
Macrocyclic salt-inducible kinase inhibitors
|
KR101548803B1
(ko)
*
|
2013-09-09 |
2015-09-01 |
경북대학교병원 |
3(6(4(트리플루오로메톡시)페닐아미노)피리미딘4일)벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
|
DK3043803T3
(da)
|
2013-09-11 |
2022-08-01 |
Univ Emory |
Nukleotid- og nucleosidsammensætninger og deres anvendelse
|
JP6595463B2
(ja)
|
2013-10-16 |
2019-10-23 |
ユニベルシテ リブレ デ ブリュッセル |
気道に影響する増殖性疾患の処置に有用な製剤
|
CN103588758A
(zh)
*
|
2013-11-04 |
2014-02-19 |
南京大学 |
一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用
|
ES2908268T3
(es)
|
2013-11-12 |
2022-04-28 |
Univ Brussel Vrije |
Vector de transcripción de ARN y sus usos
|
JP6745218B2
(ja)
|
2013-11-27 |
2020-08-26 |
レッドウッド バイオサイエンス, インコーポレイテッド |
ヒドラジニル−ピロロ化合物及び複合体を生成するための方法
|
KR101602203B1
(ko)
*
|
2014-03-11 |
2016-03-11 |
경북대학교병원 |
N(2하이드록시에틸)3(6(4(트리플루오로메톡시)페닐아미노)피리미딘-4-일)벤자미드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물
|
WO2015150337A1
(en)
|
2014-04-01 |
2015-10-08 |
Amakem Nv |
Lim kinase inhibitors
|
WO2015150472A2
(en)
|
2014-04-01 |
2015-10-08 |
Université Libre de Bruxelles |
New strategies for treating melanoma
|
WO2015161287A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use in the protection of normal cells during chemotherapy
|
CN106458821B
(zh)
|
2014-05-05 |
2019-12-31 |
爱默蕾大学 |
Bh4拮抗剂及其相关方法
|
WO2015175855A1
(en)
|
2014-05-16 |
2015-11-19 |
Emory University |
Chemokine cxcr4 and ccr5 receptor modulators and used related thereto
|
WO2016003450A1
(en)
|
2014-07-01 |
2016-01-07 |
The Regents Of The University Of California |
Pkc-epsilon inhibitors
|
EP3166955B1
(en)
|
2014-07-08 |
2018-05-02 |
Universiteit Gent |
Hamamelitannin analogues and uses thereof
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
PL3194405T4
(pl)
|
2014-09-17 |
2019-07-31 |
Oncodesign S.A. |
Makrocykliczne inhibitory kinazy lrrk2
|
MY186523A
(en)
|
2014-09-17 |
2021-07-24 |
Oncodesign Sa |
Macrocyclic rip2 kinase inhibitors
|
WO2016083490A1
(en)
|
2014-11-27 |
2016-06-02 |
Remynd Nv |
Compounds for the treatment of amyloid-associated diseases
|
JP6735751B2
(ja)
|
2014-12-15 |
2020-08-05 |
エモリー ユニバーシティー |
B型肝炎ウイルスの治療のためのホスホルアミデート
|
CA2972259A1
(en)
|
2014-12-26 |
2016-06-30 |
Emory University |
N4-hydroxycytidine and derivatives and anti-viral uses related thereto
|
WO2016146651A1
(en)
|
2015-03-16 |
2016-09-22 |
Oncodesign Sa |
Macrocyclic activin-like receptor kinase inhibitors
|
PT3288637T
(pt)
|
2015-04-28 |
2022-10-11 |
Newsouth Innovations Pty Ltd |
Visar nad+ para tratar comprometimento cognitivo, neuropatias e inatividade induzidos por quimioterapia e radioterapia
|
US10555918B2
(en)
|
2015-05-29 |
2020-02-11 |
Emory University |
2-amino-N′-benzylideneacetohydrazides and derivatives for the management of CFTR protein mediated diseases
|
CN108137595B
(zh)
*
|
2015-06-18 |
2021-04-20 |
听治疗有限责任公司 |
预防和治疗听力损失的方法和组合物
|
CA3015430A1
(en)
|
2016-02-29 |
2017-09-08 |
Oncodesign S.A. |
Radiolabeled macrocyclic egfr inhibitor
|
WO2017157882A1
(en)
|
2016-03-14 |
2017-09-21 |
Université Catholique de Louvain |
Serine biosynthetic pathway inhibitors
|
US11077110B2
(en)
|
2016-03-18 |
2021-08-03 |
Tufts Medical Center |
Compositions and methods for treating and preventing metabolic disorders
|
CN109689063A
(zh)
|
2016-04-28 |
2019-04-26 |
埃默里大学 |
含有炔烃的核苷酸和核苷治疗组合物及其相关用途
|
JP2019516715A
(ja)
|
2016-05-19 |
2019-06-20 |
ユニバーシタット アントウェルペン |
Par関連疾患の予防および/または治療における使用のためのビス(アセトアミドフェニル)グアニジノフェニルエチルホスホネート
|
BE1023757B1
(nl)
|
2016-06-30 |
2017-07-12 |
Yun NV |
Bewaring van micro-organismen
|
WO2018065387A1
(en)
|
2016-10-04 |
2018-04-12 |
Universiteit Gent |
Novel hamamelitannin analogues and uses thereof
|
WO2018071911A1
(en)
|
2016-10-14 |
2018-04-19 |
Emory University |
Nanoparticles having molecules that bind or block pd-l1 and uses in treating cancer
|
CN110049866B
(zh)
|
2016-10-26 |
2022-04-05 |
爱默蕾大学 |
多金属氧酸盐络合物在制备用于治疗癌症的药物组合物中的用途以及该药物组合物
|
WO2018096088A1
(en)
|
2016-11-24 |
2018-05-31 |
Universiteit Antwerpen |
Halogenated benzotropolones as atg4b inhibitors
|
WO2018111580A1
(en)
|
2016-12-13 |
2018-06-21 |
Emory University |
Polypeptides for managing viral infections
|
BR112019013814A2
(pt)
|
2017-01-06 |
2020-01-21 |
G1 Therapeutics Inc |
método para tratamento de câncer ou de um tumor em um indivíduo, composição farmacêutica, combinação, e, kit.
|
US20190388426A1
(en)
|
2017-01-30 |
2019-12-26 |
Université de Liège |
Perk and ire-1a inhibitors against neurodevelopmental disorders
|
IL269379B
(en)
|
2017-02-21 |
2022-06-01 |
Univ Emory |
cxcr4 receptor modulators and related uses
|
WO2018160967A1
(en)
*
|
2017-03-02 |
2018-09-07 |
Board Of Regents, The University Of Texas System |
Indolinone derivatives as inhibitors of maternal embryonic leucine zipper kinase
|
CN106977508A
(zh)
*
|
2017-05-05 |
2017-07-25 |
遵义医学院 |
具有靛红结构的吡唑衍生物用于防治肿瘤的药物及其制法
|
DK3621963T3
(da)
|
2017-05-11 |
2024-04-15 |
Remynd N V |
Forbindelser til behandling af epilepsi, neurodegenerative lidelser og andre CNS-lidelser
|
US11661581B2
(en)
*
|
2017-05-25 |
2023-05-30 |
University Of Massachusetts |
Use of CDK inhibitors to enhance growth and self-renewal of progenitor cells
|
AU2018291026B2
(en)
|
2017-06-29 |
2022-09-01 |
G1 Therapeutics, Inc. |
Morphic forms of GIT38 and methods of manufacture thereof
|
US11331331B2
(en)
|
2017-12-07 |
2022-05-17 |
Emory University |
N4-hydroxycytidine and derivatives and anti-viral uses related thereto
|
WO2019193091A1
(en)
|
2018-04-05 |
2019-10-10 |
Universiteit Hasselt |
Selective pde4d inhibitors against demyelinating diseases
|
CN112654367B
(zh)
|
2018-06-29 |
2023-08-04 |
再青春生物医药公司 |
用于年龄相关性和/或变性疾病的药物组合
|
US11987589B2
(en)
|
2018-08-07 |
2024-05-21 |
Emory University |
Heterocyclic flavone derivatives, compositions, and methods related thereto
|
SG11202101807SA
(en)
|
2018-08-24 |
2021-03-30 |
G1 Therapeutics Inc |
Improved synthesis of 1,4-diazaspiro[5.5]undecan-3-one
|
EP3843845A4
(en)
|
2018-08-29 |
2022-05-11 |
University Of Massachusetts |
INHIBITION OF PROTEIN KINASE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
|
CN113227049A
(zh)
*
|
2018-10-05 |
2021-08-06 |
艾科诺斯科技股份有限公司 |
用作map4k1抑制剂的吲哚啉酮化合物
|
US20220227757A1
(en)
|
2019-05-14 |
2022-07-21 |
Suzhou Four Health Pharmaceuticals Co., Ltd. |
Quinazoline-2,4-dione derivatives as parp inhibitors
|
MX2022010413A
(es)
|
2020-02-24 |
2022-09-07 |
Univ Leuven Kath |
Compuestos de pirrolopiridina e imidazopiridina antivirales.
|
GB202003240D0
(en)
|
2020-03-05 |
2020-04-22 |
Ecosynth Nv |
Antiviral treatment
|
US10988479B1
(en)
|
2020-06-15 |
2021-04-27 |
G1 Therapeutics, Inc. |
Morphic forms of trilaciclib and methods of manufacture thereof
|
US11857551B1
(en)
|
2020-07-10 |
2024-01-02 |
Ting Therapeutics Llc |
Methods for the prevention and treatment of hearing loss
|
WO2022157381A1
(en)
|
2021-01-25 |
2022-07-28 |
Universiteit Hasselt |
Phloretin for use in the treatment of neurodegenerative and demyelinating diseases
|
WO2022191501A1
(ko)
*
|
2021-03-12 |
2022-09-15 |
주식회사 온코크로스 |
항암제 내성 암의 치료를 위한 조성물
|
CA3227191A1
(en)
|
2021-07-26 |
2023-02-02 |
Celcuity Inc. |
1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
|
CA3227194A1
(en)
|
2021-07-30 |
2023-02-02 |
Ann De Blieck |
Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling
|
EP4387629A1
(en)
|
2021-08-18 |
2024-06-26 |
Katholieke Universiteit Leuven KU Leuven Research & Development |
6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
|
WO2023046900A1
(en)
|
2021-09-23 |
2023-03-30 |
Katholieke Universiteit Leuven |
Ribonucleoside analogues against -sars-cov-2
|
WO2023105283A1
(en)
|
2021-12-08 |
2023-06-15 |
Fundacio Privada Institut De Recerca De La Sida - Caixa |
Nucleoside reverse transcriptase inhibitors for use in down syndrome and alzheimer`s disease therapy
|
US11541071B1
(en)
|
2021-12-16 |
2023-01-03 |
Ascletis BioScience Co., Ltd |
Nucleoside derivatives and methods of use thereof
|
WO2023111683A1
(en)
|
2021-12-16 |
2023-06-22 |
Ascletis Bioscience Co., Ltd. |
N4-hydroxycytidine derivatives and use thereof as antiviral agent
|
US11760722B2
(en)
|
2022-01-18 |
2023-09-19 |
Ascletis Bioscience Co., Ltd. |
Inhibitors of cysteine proteases and methods of use thereof
|
WO2023139402A1
(en)
|
2022-01-18 |
2023-07-27 |
Ascletis Bioscience Co., Ltd. |
Inhibitors of cysteine proteases and methods of use thereof
|
WO2023180567A1
(en)
|
2022-03-24 |
2023-09-28 |
Fundacion Privada Institut De Recerca De La Sida-Caixa |
Cyclodextrins for use in coronavirus infection therapy
|
WO2023241799A1
(en)
|
2022-06-15 |
2023-12-21 |
Université Libre de Bruxelles |
Flavanols for use in the treatment of retroviral infections
|
US20240025885A1
(en)
|
2022-07-08 |
2024-01-25 |
Ascletis BioScience Co., Ltd |
Triazine derivatives and methods of use thereof
|
CN116514783A
(zh)
|
2022-11-21 |
2023-08-01 |
歌礼生物科技(杭州)有限公司 |
三嗪衍生物
|